Adaptive Biotechnologies raises 2026 MRD revenue view to $260M-$270M while targeting positive adjusted EBITDA and free cash flow by end of 2026

EarningsMRDPositive

AI Analysis

Summary

Adaptive Biotechnologies raised its 2026 MRD revenue guidance to $260M-$270M and expects to achieve positive adjusted EBITDA and free cash flow by year-end 2026.

Financial Highlights

Revenue

$260M-$270M

Guidance

MRD revenue 2026: $260M-$270M; targeting positive adjusted EBITDA and free cash flow by end of 2026

Importance:5/10

Sentiment:

0.70

guidancerevenue_forecastprofitability_targetMRD

Related Companies

$ADPT

Read the original article

Published by Seeking Alpha Healthcare on May 6, 2026 2:22 AM

Read Original